Prospective Study of Quality of Life of Patients Receiving Treatment for Prostate Cancer
Prospective Study of Quality of Life of Patients Receiving Treatment for Prostate Cancer
复制标题
接受前列腺癌治疗的患者生活质量的前瞻性研究
DOI：
10.1097/00006199-200603001-00006
复制
发表时间：
2006
期刊：
影响因子：
2.5
通讯作者：
I. Sawczuk
中科院分区：
文献类型：
--
作者：
L. Eller;E. Lev;G. Gejerman;J. Colella;M. Esposito;V. Lanteri;John Scheuch;R. Munver;Patricia Lane;Claudia Junchaya;L. Alves;B. Galli;Richard Watson;I. Sawczuk
背景资料：没有研究发现接受调强放疗的前列腺癌患者与接受根治性前列腺切除术的前列腺癌患者的生活质量（QOL）结局进行了比较。目的：（a）描述三种类型的前列腺癌治疗前后的QOL差异：根治性前列腺切除术、调强放射治疗+粒子植入（永久性近距离放射治疗）或调强放射治疗+高剂量率放射治疗（临时性近距离放射治疗）;和（B）研究影响前列腺癌男性QOL的人口统计学、身体和心理社会变量。方法：在三种情况下收集数据：基线（治疗前），1个月和开始治疗后3个月。措施包括传记数据，生理和心理措施。方差分析和分层回归被用来检查模式，描述差异，并确定三个治疗组的生活质量的预测因子。QOL被概念化为一个多维结构，包括身体，心理，社会和功能健康和前列腺癌的关注。结果如下：两组在基线时的肠道和泌尿系统症状评分和前列腺癌关注方面存在显著差异，在3个月时的泌尿系统和抑郁症状方面存在显著差异。1个月时无显著组间差异。讨论内容：采用癌症治疗功能评估-前列腺进行根治性前列腺切除术、调强放射治疗+粒子植入或调强放射治疗+高剂量率放射治疗后，发现QOL存在显著差异。研究结果可以为医疗保健提供者提供有关前列腺癌治疗后遗症的知识，使医疗保健提供者能够教育患者前列腺癌治疗的QOL结果，并使患者能够做出更明智的治疗决定。
Background: No research was found that compared quality of life (QOL) outcomes of prostate cancer patients receiving intensity-modulated radiation therapies with prostate cancer patients receiving radical prostatectomy. Objectives: To (a) describe differences in QOL before and after three types of treatment for prostate cancer: radical prostatectomy, intensity-modulated radiation therapy + seed implantation (permanent brachytherapy), or intensity-modulated radiation therapy + high dose rate radiotherapy (temporary brachytherapy); and (b) investigate demographic, physical, and psychosocial variables that impact QOL of men with prostate cancer. Methods: Data were collected on three occasions: baseline (prior to treatment), 1 month, and 3 months after beginning treatment. Measures included biographic data, physiological, and psychological measures. Analysis of variance and hierarchical regression were used to examine patterns, describe differences, and identify predictors of QOL in the three treatment groups. QOL was conceptualized as a multidimensional construct that included physical, psychological, social, and functional well-being and prostate cancer concerns. Results: Groups differed significantly in bowel and urinary symptom scores and prostate cancer concerns at baseline, and in urinary and depressive symptoms at 3 months. There were no significant group differences at 1 month. Discussion: Significant differences were found in QOL as measured with the Functional Assessment of Cancer Treatment-Prostate after treatment with radical prostatectomy, intensity-modulated radiation therapy + seed implantation, or intensity-modulated radiation therapy + high dose rate radiotherapy. Findings may provide healthcare providers with knowledge about treatment sequelae for prostate cancer, enable healthcare providers to educate patients about QOL outcomes of treatment for prostate cancer, and enable patients to make more informed treatment decisions.